Eli Lilly Statistics
Total Valuation
Eli Lilly has a market cap or net worth of $900.85 billion. The enterprise value is $924.82 billion.
| Market Cap | 900.85B |
| Enterprise Value | 924.82B |
Important Dates
The last earnings date was Wednesday, February 4, 2026, before market open.
| Earnings Date | Feb 4, 2026 |
| Ex-Dividend Date | Feb 13, 2026 |
Share Statistics
Eli Lilly has 893.36 million shares outstanding. The number of shares has decreased by -0.53% in one year.
| Current Share Class | 893.36M |
| Shares Outstanding | 893.36M |
| Shares Change (YoY) | -0.53% |
| Shares Change (QoQ) | -0.09% |
| Owned by Insiders (%) | 0.17% |
| Owned by Institutions (%) | 88.59% |
| Float | 891.01M |
Valuation Ratios
The trailing PE ratio is 43.94 and the forward PE ratio is 29.09. Eli Lilly's PEG ratio is 1.18.
| PE Ratio | 43.94 |
| Forward PE | 29.09 |
| PS Ratio | 13.63 |
| Forward PS | 11.35 |
| PB Ratio | 33.40 |
| P/TBV Ratio | 62.94 |
| P/FCF Ratio | 99.02 |
| P/OCF Ratio | 52.84 |
| PEG Ratio | 1.18 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 29.18, with an EV/FCF ratio of 103.08.
| EV / Earnings | 44.81 |
| EV / Sales | 14.19 |
| EV / EBITDA | 29.18 |
| EV / EBIT | 31.14 |
| EV / FCF | 103.08 |
Financial Position
The company has a current ratio of 1.58, with a Debt / Equity ratio of 1.65.
| Current Ratio | 1.58 |
| Quick Ratio | 0.78 |
| Debt / Equity | 1.65 |
| Debt / EBITDA | 1.37 |
| Debt / FCF | 4.89 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 101.16% and return on invested capital (ROIC) is 39.82%.
| Return on Equity (ROE) | 101.16% |
| Return on Assets (ROA) | 19.42% |
| Return on Invested Capital (ROIC) | 39.82% |
| Return on Capital Employed (ROCE) | 38.44% |
| Weighted Average Cost of Capital (WACC) | 6.32% |
| Revenue Per Employee | $1.30M |
| Profits Per Employee | $412,800 |
| Employee Count | 50,000 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 1.04 |
Taxes
In the past 12 months, Eli Lilly has paid $5.09 billion in taxes.
| Income Tax | 5.09B |
| Effective Tax Rate | 19.79% |
Stock Price Statistics
The stock price has increased by +15.96% in the last 52 weeks. The beta is 0.43, so Eli Lilly's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | +15.96% |
| 50-Day Moving Average | 1,045.87 |
| 200-Day Moving Average | 882.22 |
| Relative Strength Index (RSI) | 46.43 |
| Average Volume (20 Days) | 3,048,414 |
Short Selling Information
The latest short interest is 6.38 million, so 0.71% of the outstanding shares have been sold short.
| Short Interest | 6.38M |
| Short Previous Month | 7.70M |
| Short % of Shares Out | 0.71% |
| Short % of Float | 0.72% |
| Short Ratio (days to cover) | 1.81 |
Income Statement
In the last 12 months, Eli Lilly had revenue of $65.18 billion and earned $20.64 billion in profits. Earnings per share was $22.95.
| Revenue | 65.18B |
| Gross Profit | 54.13B |
| Operating Income | 29.70B |
| Pretax Income | 25.73B |
| Net Income | 20.64B |
| EBITDA | 31.69B |
| EBIT | 29.70B |
| Earnings Per Share (EPS) | $22.95 |
Balance Sheet
The company has $7.27 billion in cash and $43.87 billion in debt, with a net cash position of -$36.37 billion or -$40.72 per share.
| Cash & Cash Equivalents | 7.27B |
| Total Debt | 43.87B |
| Net Cash | -36.37B |
| Net Cash Per Share | -$40.72 |
| Equity (Book Value) | 26.54B |
| Book Value Per Share | 29.65 |
| Working Capital | 20.40B |
Cash Flow
In the last 12 months, operating cash flow was $16.81 billion and capital expenditures -$7.84 billion, giving a free cash flow of $8.97 billion.
| Operating Cash Flow | 16.81B |
| Capital Expenditures | -7.84B |
| Free Cash Flow | 8.97B |
| FCF Per Share | $10.04 |
Margins
Gross margin is 83.04%, with operating and profit margins of 45.56% and 31.67%.
| Gross Margin | 83.04% |
| Operating Margin | 45.56% |
| Pretax Margin | 39.48% |
| Profit Margin | 31.67% |
| EBITDA Margin | 48.62% |
| EBIT Margin | 45.56% |
| FCF Margin | 13.77% |
Dividends & Yields
This stock pays an annual dividend of $6.92, which amounts to a dividend yield of 0.69%.
| Dividend Per Share | $6.92 |
| Dividend Yield | 0.69% |
| Dividend Growth (YoY) | 15.37% |
| Years of Dividend Growth | 11 |
| Payout Ratio | 27.15% |
| Buyback Yield | 0.53% |
| Shareholder Yield | 1.23% |
| Earnings Yield | 2.32% |
| FCF Yield | 1.01% |
Analyst Forecast
The average price target for Eli Lilly is $1,174.53, which is 16.48% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $1,174.53 |
| Price Target Difference | 16.48% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (5Y) | 14.71% |
| EPS Growth Forecast (5Y) | 21.80% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 16, 1997. It was a forward split with a ratio of 2:1.
| Last Split Date | Oct 16, 1997 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Eli Lilly has an Altman Z-Score of 7.16 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.16 |
| Piotroski F-Score | 6 |